MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • RAB12 variants and their role in dystonia

    K. Lohmann, E. Hebert, F. Borngräber, A. Schmidt, A. Rakovic, A. Weissbach, J. Hampf, E.-J. Vollstedt, S. Schaake, H. Manzoor, H.-C. Jabusch, M. Kasten, V. Kostic, T. Gasser, K. Zeuner, P. Bauer, E. Altenmüller, C. Klein (Luebeck, Germany)

  • Randomize study of occurrence of Parkinson’s syndrome in patients with rheumatoid arthritis.

    M. Mavlanov, S. Aslanova, G. Rakhimbaeva (Tashkent, Uzbekistan)

  • Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

    T.G. Study Group (Bristol, United Kingdom)

  • Rapidly progressive dementia and parkinsonism caused by a cortical dural AV fistula: a case report

    T. Weissfeld, D. Kremens, J. McCall (Philadelphia, PA, USA)

  • Rare presentation of acute secondary parkinsonism in the post partum period.

    D. Desai, S. Desai (Anand, India)

  • Rare variant analysis of the PPMI dataset to uncover the complex genetic architecture of Parkinson’s disease

    d. BOBBILI, P. MAY, R. KRUEGER (Esch-sur-Alzette, Luxembourg)

  • Rationale and Design of a Phase 2 Study to Evaluate the Efficacy of Intepirdine (RVT-101) in Improving Gait and Balance in Patients with Dementia

    S. Ramaswamy, N. Bohnen, M. Muller, I. Lombardo, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

  • RBD predicts the cognitive impairment in Parkinson’s disease

    E. Stefanova, T. Stojkovic, I. Stankovic, V. Kostic (Belgrade, Serbia)

  • Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of DBS for Parkinson’s disease

    G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, M. Pötter-Nerger, L. Timmermann, J. Volkmann, A. Kühn, P. Eldridge, J. Fitzgerald, H. Mehdorn, J. Vesper (Kiel, Germany)

  • Real-world non-motor score changes in Parkinson’s disease patients with motor fluctuations: The J-FIRST study

    H. Watanabe, H. Saiki, S.-W. Chiu, T. Yamaguchi, K. Kashihara, Y. Tsuboi, M. Nomoto, N. Hattori, T. Maeda, Y. Shimo (Nagoya, Japan)

  • Reappraisal of cortical myoclonus: a retrospective study of clinical neurophysiology

    A. Latorre, L. Rocchi, A. Berardelli, K. Bhatia, C. Cordivari (London, United Kingdom)

  • Reappraisal of Progressive Myoclonus Ataxia

    S. vd Veen, R. Zutt, T. De Koning, M. Tijssen (Groningen, Netherlands)

  • Redefining social work for Parkinson’s: the development of a model of care for specialized support in the clinic, community and home

    A. Lemen, LCSW, M. Sweeney, LMSW, V. Luce, LCSW, D. Rayment, LMSW, A. Di Rocco (New York, NY, USA)

  • Regional differences may influence the drivers of change in Toronto Western Spasmodic Rating Scale (TWSTRS) scores following botulinum toxin treatment: Analysis of an international observational study

    V. Misra, D. Charles, T.M. Chung, C. Colosimo, S. Om, P. Maisonobe (London, United Kingdom)

  • Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates

    A. Singh, S. Papa (Minneapolis, MN, USA)

  • Rehabilitation program with or without a whey protein-based nutritional support enriched with essential aminoacids and vitamin D in patients with Parkinson’s disease or parkinsonism: study design of a randomized, controlled trial.

    m. barichella, E. Cereda, G. Pinelli, l. Iorio, V. Ferri, g. Frazzitta, E. Cassani, G. Riboldazzi, G. Pezzoli (Milano, Italy)

  • Relation between REM-Sleep Behaviour Disorder and dysautonomic symptoms in Essential Tremor patients

    R. Barbosa, M. Mendonça, F. Ladeira, R. Miguel, P. Bugalho (Lisboa, Portugal)

  • Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson’s disease

    H. Sawada, S. Orimo, A. Inaba, M. Takahashi (Tokyo, Japan)

  • Relationship between Insulin-like Growth Factor-1 and characteristics of physical activity in patients with Parkinson’s disease

    K. Nagaki, M. Ikenaga, S. Fujioka, Y. Tsuboi (fukuoka, Japan)

  • Relationship between neuropsychological functioning and subjective measures of sleep quality in Parkinson Disease

    E. Montanaro, M. Zibetti, F. Dematteis, L. Lopiano (Torino, Italy)

  • Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease

    M. Iijima, H. Yoshizawa, Y. Uchiyama, K. Abe, K. Kitagawa (Tokyo, Japan)

  • Relationship between sensory augmentation and exercise routine in the improvement in balance and gait in a patient with lithium-induced ataxia

    M. Maldonado (Santiago, Chile)

  • Relationship between sleep profiles and clinical features in Parkinson’s disease

    Y.-Y. Lin, R.-S. Chen, C.-S. Lu, Y.-Z. Huang, Y.-H. Weng, T.-H. Yeh, W.-Y. Lin, J. Hung (Taoyuan, Taiwan)

  • Relationship between the presence of colonic a-synuclein and MDS research criteria for prodromal PD in patients without manifest motor parkinsonism (PARCAS study)

    M. Skorvanek, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, B. Kolarova, B. Repkova, Z. Urbancikova, A. Vargova, L. Gombosova, M. Zakuciova, E. Veseliny, F. Trebuna, E. Mechirova, Z. Gdovinova (Kosice, Slovakia)

  • Relationship of metabolic markers in Parkinson’s disease

    N. Alsomali, A. Mujtaba, A. AlSamrani, S. Marar, T. Mohammad (Riaydh, Saudi Arabia)

  • Reliability of Continuous Parkinson’s Assessment Using Wearables

    D. Heldman, E. Urrea Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, A. Hadley, Z. Mari, M. Burack, I. Itin, F. Revilla (Cleveland, OH, USA)

  • REM sleep behavior disorder: Is it useful to differentiate between Parkinson disease and Progressive Supranuclear Palsy?

    H. Gupta, S. Mehta, J. Hentz, H. Shill, E. Driver-Dunckley, M. Sabbagh, C. Belden, B. Dugger, T. Beach, G. Serrano, L. Sue, C. Adler (Scottsdale, AZ, USA)

  • Reproducibility of data-driven Parkinson’s disease subtypes for clinical research using a Delphi process for expert-based consensus.

    T. Mestre, S. Eberly, C. Tanner, A. Lang, D. Grimes, D. Oakes, C. Marras (Ottawa, ON, Canada)

  • Research on Relationship between Sensory Tricks of Cervical Dystonia and Function of Cerebral Cortex

    T. Li, Z. Liang, C. Song, L. Zhou, L. Jing (Dalian, China)

  • Research participants are not representative of the population age distribution of PD

    A. Macleod, R. Henery, P. Nwajiugo, C. Counsell (Aberdeen, United Kingdom)

  • Resting state functional connectivity in PD patients with and without Freezing of gait

    K. Bharti, A. Suppa, N. Upadhyay, S. Pietracupa, G. Leodori, A. Zampogna, C. Gianni, N. Petsas, A. Berardelli, P. Pantano (Rome, Italy)

  • Resting state modulations of EEG low frequency bands in Parkinson’s disease.

    A. Pal, N. Mehta, R. Sharma (New Delhi, India)

  • Restless Legs Syndrome in Functional Movement Disorders

    T. Serranova, M. Slovak, D. Kemlink, K. Sonka, E. Ruzicka (Prague, Czech Republic)

  • Restless Legs Syndrome in hemodialyzed patients: a case-control study.

    I. Estrada-Bellmann, S. Castillo-Torres, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías (Monterrey, Mexico)

  • Restless legs syndrome in pregnancy: frequency and impact on quality of life and sleep

    S. Telarovic, L. Condic, I. Telarovic (Zagreb, Croatia)

  • Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

    J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

  • Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design

    N. Mendonca, T. West, J. Braunstein, I. Fogelman, Y. Bordelon, I. Litvan, E. Roberson, H. Hu, P. Verghese, R. Bateman, H. Florian, D. Wang, D. Ryman, L. Gault, K. Budur, B. Rendenbach-Mueller, D. Kerwin, A. Boxer, D. Holtzman (Ludwigshafen, Germany)

  • Reversible progressive supranuclear palsy-mimic induced by risperidone

    H.J. Kim, J.H. Lee (Seoul, Republic of Korea)

  • Reviewing the Clinical and Mutational Spectrum of SLC20A2 Mutations in Primary Familial Brain Calcification (PFBC) for MDSGene

    A. Balck, S. Schaake, C. Marras, C. Lill, A. Westenberger, C. Klein (Luebeck, Germany)

  • Rice bran extract against animal model of Huntington’s disease: Possible role of neurotransmitters

    P. Kumar, N. Kaur (Bathinda, Punjab, India)

  • Riding the puzzle: deep brain stimulation and the non-motor symptoms in Parkinson’s disease

    A.C. Campos, E. Talamoni Fonoff, C. Hamani, R. Lima Pagano (São Paulo, Brazil)

  • Risk Factors for Dementia in Parkinson’s disease

    M.I. Khalil, M.R. Rahman, S. Munira (Dhaka, Bangladesh)

  • Risk of Parkinson’s disease in zolpidem user: A systematic review and meta-analysis

    S. Hussain, A.K. Najmi, D. Anil (New Delhi, India)

  • Role of Apocyanin in modulating glial cell functions and associated inflammatory response in Lipopolysaccharide induced Parkinson’s disease model.

    N. Sharma, B. Nehru (Chandigarh, India)

  • Role of the subthalamic nucleus and globus pallidus internus in response inhibition during masked prime tasks in human

    A. Singh, I. Niazi, V. Sharma, K. Boetzel (Minneapolis, MN, USA)

  • Rolipram, a PDE-IV inhibitor protects against experimental Parkinsonism in mice

    N. KUMAR, R. Khanna (Jaipur, India)

  • Rotenone induces astrocyte-mediated non-cell autonomous dopaminergic neurotoxicity

    I. Miyazaki, S. Murakami, R. Kikuoka, N. Isooka, Y. Kitamura, M. Asanuma (Okayama, Japan)

Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley